Focused On-demand Library for Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q8TBX8

UPID:

PI42C_HUMAN

Alternative names:

Phosphatidylinositol 5-phosphate 4-kinase type II gamma

Alternative UPACC:

Q8TBX8; B2RDL3; B4DM11; B4DY44; Q9H6N2

Background:

Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, also known as Phosphatidylinositol 5-phosphate 4-kinase type II gamma, plays a pivotal role in cellular processes by regulating phosphatidylinositol phosphate metabolism. Its enzymatic activity, though low, is crucial for maintaining cellular functions, with a preference for GTP over ATP. This protein's interaction with PIP5Ks modulates insulin signaling, highlighting its importance in metabolic pathways.

Therapeutic significance:

Understanding the role of Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma could open doors to potential therapeutic strategies. Its involvement in insulin signaling pathways suggests a possible impact on metabolic disorders, making it a target of interest for drug discovery efforts aimed at regulating insulin sensitivity and addressing metabolic diseases.